Skp2 Suppresses Apoptosis in Rb1-deficient Tumours by Limiting E2F1 Activity

Overview

Journal Nat Commun

Specialty Biology

Date 2014 Mar 18

PMID 24632684

Citations 29

Authors

Zhonglei Lu

Frederick Bauzon

Hao Fu

Jinhua Cui

Hongling Zhao

Keiko Nakayama

Keiich I Nakayama

Liang Zhu

Affiliations

Soon will be listed here.

Abstract

One mechanism of tumour suppression by pRb is repressing E2F1. Hence, E2f1 deletion diminishes tumorigenesis following Rb1 loss. However, E2F1 promotes both proliferation and apoptosis. It therefore remains unclear how de-repressed E2F1 promotes tumorigenesis. Another mechanism of pRb function is repressing Skp2 to elevate p27 to arrest proliferation. However, Skp2 deletion induced apoptosis, not proliferation arrest, in Rb1-deficient pituitary tumorigenesis. Here we show that Rb1 deletion induces higher expression of E2F1 target genes in the absence of Skp2. E2F1 binds less cyclin A but more target promoters when Rb1 is deleted with Skp2 knockout or p27T187A knockin, suggesting that stabilized p27 prevents cyclin A from binding and inhibiting E2F1. In Rb1-deficient pituitary tumorigenesis, Skp2 deletion or p27T187A mutation converts E2F1's role from proliferative to apoptotic. These findings delineate a pRb-Skp2-p27-cyclin A-E2F1 pathway that determines whether E2F1 is proliferative or apoptotic in Rb1-deficient tumorigenesis.

Citing Articles

Distinct outcomes from targeted perturbations of the multi-subunit SCF E3 ubiquitin ligase in blocking Trp53/Rb1-null prostate tumorigenesis.

Xue Y, Zhu L, Karan S, Locker J, Branch C, Zhang J Commun Biol. 2025; 8(1):278.

PMID: 39987265 PMC: 11846996. DOI: 10.1038/s42003-025-07662-3.

Targeted inhibition of SCF confers anti-tumor activities resulting in a survival benefit in osteosarcoma.

Wang J, Ferrena A, Zhang R, Singh S, Viscarret V, Al-Harden W Oncogene. 2024; 43(13):962-975.

PMID: 38355807 PMC: 10959747. DOI: 10.1038/s41388-024-02942-4.

Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review.

Jing J, Rui L, Junyuan S, Jinfeng Y, Zhihao H, Weiguo L Front Pharmacol. 2023; 14:1122008.

PMID: 37089937 PMC: 10113621. DOI: 10.3389/fphar.2023.1122008.

Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST.

Schaefer I, Hemming M, Lundberg M, Serrata M, Goldaracena I, Liu N Br J Cancer. 2022; 127(11):2072-2085.

PMID: 36175617 PMC: 9681737. DOI: 10.1038/s41416-022-01990-5.

MicroRNA-205-5p targets E2F1 to promote autophagy and inhibit pulmonary fibrosis in silicosis through impairing SKP2-mediated Beclin1 ubiquitination.

Qian Q, Ma Q, Wang B, Qian Q, Zhao C, Feng F J Cell Mol Med. 2021; 25(19):9214-9227.

PMID: 34428336 PMC: 8500965. DOI: 10.1111/jcmm.16825.

References

Sage J, Miller A, Perez-Mancera P, Wysocki J, Jacks T . Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature. 2003; 424(6945):223-8. DOI: 10.1038/nature01764. View

Yeh K, Kondo T, Zheng J, Tsvetkov L, Blair J, Zhang H . The F-box protein SKP2 binds to the phosphorylated threonine 380 in cyclin E and regulates ubiquitin-dependent degradation of cyclin E. Biochem Biophys Res Commun. 2001; 281(4):884-90. DOI: 10.1006/bbrc.2001.4442. View

Denchi E, Helin K . E2F1 is crucial for E2F-dependent apoptosis. EMBO Rep. 2005; 6(7):661-8. PMC: 1369111. DOI: 10.1038/sj.embor.7400452. View

Yung Y, Walker J, Roberts J, Assoian R . A Skp2 autoinduction loop and restriction point control. J Cell Biol. 2007; 178(5):741-7. PMC: 2064539. DOI: 10.1083/jcb.200703034. View

Kitagawa M, Lee S, McCormick F . Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol Cell. 2008; 29(2):217-31. DOI: 10.1016/j.molcel.2007.11.036. View

Sun D, Melegari M, Sridhar S, Rogler C, Zhu L . Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown. Biotechniques. 2006; 41(1):59-63. DOI: 10.2144/000112203. View

Lin W, Cao J, Liu J, Beshiri M, Fujiwara Y, Francis J . Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A. 2011; 108(33):13379-86. PMC: 3158206. DOI: 10.1073/pnas.1110104108. View

Lu Z, Marcelin G, Bauzon F, Wang H, Fu H, Dun S . pRb is an obesity suppressor in hypothalamus and high-fat diet inhibits pRb in this location. EMBO J. 2013; 32(6):844-57. PMC: 3604720. DOI: 10.1038/emboj.2013.25. View

Ji P, Goldin L, Ren H, Sun D, Guardavaccaro D, Pagano M . Skp2 contains a novel cyclin A binding domain that directly protects cyclin A from inhibition by p27Kip1. J Biol Chem. 2006; 281(33):24058-69. DOI: 10.1074/jbc.M603105200. View

10.

Besson A, Hwang H, Cicero S, Donovan S, Gurian-West M, Johnson D . Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev. 2007; 21(14):1731-46. PMC: 1920168. DOI: 10.1101/gad.1556607. View

11.

Ziebold U, Lee E, Bronson R, Lees J . E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas. Mol Cell Biol. 2003; 23(18):6542-52. PMC: 193688. DOI: 10.1128/MCB.23.18.6542-6552.2003. View

12.

Zhang L, Wang C . F-box protein Skp2: a novel transcriptional target of E2F. Oncogene. 2005; 25(18):2615-27. PMC: 1513044. DOI: 10.1038/sj.onc.1209286. View

13.

Nicolay B, Gameiro P, Tschop K, Korenjak M, Heilmann A, Asara J . Loss of RBF1 changes glutamine catabolism. Genes Dev. 2013; 27(2):182-96. PMC: 3566311. DOI: 10.1101/gad.206227.112. View

14.

Zhao H, Bauzon F, Fu H, Lu Z, Cui J, Nakayama K . Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors. Cancer Cell. 2013; 24(5):645-59. PMC: 3880806. DOI: 10.1016/j.ccr.2013.09.021. View

15.

Morris E, Dyson N . Retinoblastoma protein partners. Adv Cancer Res. 2001; 82:1-54. DOI: 10.1016/s0065-230x(01)82001-7. View

16.

Dynlacht B, Flores O, Lees J, Harlow E . Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev. 1994; 8(15):1772-86. DOI: 10.1101/gad.8.15.1772. View

17.

Xu M, Sheppard K, Peng C, Yee A, Piwnica-Worms H . Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol Cell Biol. 1994; 14(12):8420-31. PMC: 359381. DOI: 10.1128/mcb.14.12.8420-8431.1994. View

18.

Malek N, Sundberg H, McGrew S, Nakayama K, Kyriakides T, Roberts J . A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature. 2001; 413(6853):323-7. DOI: 10.1038/35095083. View

19.

Lowe S, Cepero E, Evan G . Intrinsic tumour suppression. Nature. 2004; 432(7015):307-15. DOI: 10.1038/nature03098. View

20.

Krek W, Ewen M, Shirodkar S, Arany Z, Kaelin Jr W, Livingston D . Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell. 1994; 78(1):161-72. DOI: 10.1016/0092-8674(94)90582-7. View